Please login to the form below

Not currently logged in
Email:
Password:

Merck's new insomnia drug clears phase III trial

Novel method of treatment offers fewer side effects

Merck & Co has moved a step closer to bringing its novel insomnia drug suvorexant to market after reporting positive data in a phase III trial.

The company is now on track to file for approval of suvorexant before the end of the year, with a chance of bringing to market the first drug for insomnia treatment that does not work by enhancing the activity of the neurotransmitter GABA.

Suvorexant acts as an antagonist of orexin, a hormone that seems causes wakefulness, and is thought to avoid many of the side effects of current insomnia drugs such as next-day drowsiness, sleep walking, and dependency.

The latest data come from a 12-month, placebo-controlled study of suvorexant that was designed to assess safety and long-term efficacy.

Earlier studies have already supported its short-term efficacy, and Merck wanted to show that these benefits were maintained, and also to demonstrate that suvorexant was free of safety concerns that led to the discontinuation of GlaxoSmithKline (GSK) and Actelion's rival orexin antagonist almorexant.

The results showed that patients who had been taking suvorexant for 12 months and were switched to placebo saw their insomnia return, but clinically meaningful withdrawal symptoms and rebound insomnia did not emerge.

"What happens when patients stop taking a sleep medication is a key concern for both patients and healthcare professionals," said study investigator James Walsh of Stanford University School of Medicine.

Insomnia drugs represent a multibillion dollar market worldwide, but the sector has been eroded in recent years by the launch of generic versions of one of the big GABA-modulating drugs - zolpidem - and will experience another shift when Eisai's Lunesta (eszopiclone) starts to lose patent protection later this year.

If approved with a claim for greater tolerability, suvorexant could be a major new product for Merck with sales in excess of $1bn.

Suvorexant is one of five new drugs the company hopes to bring to market or file 2012 and 2013, along with vorapaxar, an experimental drug for acute coronary syndrome chest pain caused by coronary artery disease), HPV vaccine V503, osteoporosis treatment odanacatib and atherosclerosis medicine Tredaptive ER.

13th September 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four MSA

Four MSA creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal approach....

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics